Position in NVS
as of Jun 30, 2026
· filed Jul 2, 2026
Position Value
$16,455
+$3,319 QoQ
Shares Held
105
+22.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#1,502
of 1,603 holders
Holding Since
Mar 2023
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cedar Mountain Advisors, LLC holds $655,207 across 12 Drug Manufacturers - General names. NVS ranks #8 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
630 | $158,533 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,215 | $156,127 | |
| 3 | JNJ |
Johnson & Johnson
|
482 | $122,413 | |
| 4 | LLY |
ELI LILLY & Co
|
69 | $82,760 | |
| 5 | PFE |
Pfizer Inc
|
1,691 | $40,719 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
271 | $34,238 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
363 | $20,916 | |
| 8 | NVS |
Novartis AG
This page
|
105 | $16,455 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,455 | 105 | Shares | Sole | 2026-07-02 | |
| 2026-03-31 | $13,136 | 86 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $19,163 | 139 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $18,210 | 142 | Shares | Sole | 2025-10-24 | |
| 2023-06-30 | $7,063 | 70 | Shares | Sole | 2023-07-19 | |
| 2023-03-31 | $7,268 | 79 | Shares | Sole | 2023-04-11 | |
| No filing history on record for this holder in this stock. | ||||||